Want to see HK:3933 full AI Analyst Report?
3933 Stock Chart & Stats
HK$11.74
HK$0.26(2.23%)
At close: 4:00 PM EST
HK$11.74
HK$0.26(2.23%)
Day’s Range― - ―
52-Week RangeHK$7.98 - HK$17.98
Previous CloseN/A
Volume6.42M
Average Volume (3M)9.98M
Market Cap
HK$16.63B
Enterprise ValueHK$7.94B
Total Cash (Recent Filing)HK$11.24B
Total Debt (Recent Filing)HK$4.99B
Price to Earnings (P/E)6.4
Beta0.82
Next Earnings
Aug 27, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend Yield5.11%
Share Statistics
EPS (TTM)1.14
Shares Outstanding1,973,026,500
10 Day Avg. Volume7,816,257
30 Day Avg. Volume9,977,158
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$15.57Price Target Upside32.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.64
Revenue Forecast (FY)HK$12.79B
Bulls Say, Bears Say
Bulls Say
Gross Margin ResilienceA ~42% gross margin in 2025 indicates sustained product-level profitability and likely pricing power or cost advantage in manufacturing. This margin base supports long-term earnings resilience, funding for R&D and commercial investments even if top-line growth moderates.
Conservative Balance Sheet LeverageModerate debt-to-equity (0.12–0.29) and steadily building equity provide financial flexibility to weather cycles and fund strategic initiatives. A conservatively levered balance sheet preserves access to capital and reduces refinancing risk over a multi-quarter horizon.
Positive Operating Cash Flow TrendConsistently positive and generally growing operating cash flow underpins the core business's cash-generating ability. That durable cash generation supports dividends, maintenance capex and selective reinvestment without immediate reliance on external financing.
Bears Say
Recent Revenue DeclineAn ~8.7% revenue decline in 2025 following flat 2024 signals a material slowdown in demand or losing share. Sustained top-line weakness can erode operating leverage, limit reinvestment capacity and force pricing or cost restructuring that hurts long-term growth prospects.
Weak And Volatile Free Cash Flow ConversionFree cash flow materially below net income and volatile (about 23% in 2025) undermines earnings quality and constrains the company’s ability to sustainably fund dividends, debt reduction and R&D. Persistent weak conversion raises financing and strategic risks.
Declining ROE And Margin CompressionA sharp ROE decline and margin compression over recent periods indicate reduced effectiveness at converting capital into profit. This deterioration can reflect pricing pressures, higher costs, or product mix shifts that weaken long-term return potential unless addressed structurally.
The United Laboratories International Holdings News
3933 FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was HK$7.98 and its highest was HK$17.98 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is HK$16.63B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Aug 27, 2026 which is in 57 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Mar 24, 2026. The company reported HK$0.127 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.058.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of HK$0.269 which represents an annual dividend yield of 5.11%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.5.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,973,026,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of HK$0.127 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went up 2.277%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in HK:3933
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$15.57 (32.59% Upside)
HK$15.57 (32.59% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.38%
12-Months-Change
Fundamentals
Return on Equity
12.65%
Trailing 12-Months
Asset Growth
24.94%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
3933 Stock 12 Month Forecast
Average Price Target
HK$15.57
▲(32.59% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---